文献速递间质性肺疾病呼吸道感染

特发性肺纤维化肺移植受者短端粒与巨细胞病毒免疫受损

Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

研究比较42例IPF肺移植受者与42例年龄匹配非IPF受者的CMV结局,发现IPF组复发性CMV病毒血症发生率69% vs 31%,短端粒者CMV并发症风险最高,且CMV特异性T细胞增殖、效应功能及T-bet诱导显著受损,提示端粒介导的全身免疫缺陷。

要点

  • IPF肺移植受者复发性CMV病毒血症风险显著高于非IPF受者(OR 4.98)。
  • 短端粒IPF受者CMV并发症风险最高,包括复发性病毒血症、终末器官病和耐药。
  • 短端粒缺陷与CMV特异性T细胞增殖和效应功能受损相关。

核心结论

  • IPF肺移植受者中短端粒缺陷与CMV特异性T细胞免疫受损及病毒控制不良相关。
  • 短端粒缺陷可能是端粒介导疾病在IPF患者中的全身表现。

研究设计与样本

  • 研究纳入IPF肺移植受者42例和年龄匹配非IPF肺移植受者42例。
  • 检测淋巴细胞端粒长度和DNA测序,并用流式细胞术和荧光原位杂交评估CMV特异性T细胞免疫。

主要发现

  • IPF受者复发性CMV病毒血症发生率为69%,非IPF受者为31%(OR 4.98,95%CI 1.95-12.50,P<0.001)。
  • 短端粒IPF受者CMV并发症风险最高(P<0.01),包括复发性病毒血症、终末器官病和CMV治疗耐药。
  • 短端粒IPF受者至病毒血症时间短于年龄匹配非IPF对照(P<0.001)。
  • 短端粒缺陷与CMV特异性增殖反应、T细胞效应功能及T-bet(TBX21)诱导显著受损相关。

临床怎么用

  • 识别短端粒IPF肺移植受者这一高危亚组,有助于风险评估和管理。
  • 针对该亚组可考虑制定策略以预防移植后CMV并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Cytomegalovirus (CMV)-related morbidities remain one of the most common complications after lung transplantation and have been linked to allograft dysfunction, but the factors that predict high risk for CMV complications and effective immunity are incompletely understood. OBJECTIVES: To determine if short telomeres in idiopathic pulmonary fibrosis (IPF) lung transplant recipients (LTRs) predict the risk for CMV-specific T-cell immunity and viral control. METHODS: We studied IPF-LTRs (n = 42) and age-matched non-IPF-LTRs (n = 42) and assessed CMV outcomes. We measured lymphocyte telomere length and DNA sequencing, and assessed CMV-specific T-cell immunity in LTRs at high risk for CMV events, using flow cytometry and fluorescence in situ hybridization. MEASUREMENTS AND MAIN RESULTS: We identified a high prevalence of relapsing CMV viremia in IPF-LTRs compared with non-IPF-LTRs (69% vs. 31%; odds ratio, 4.98; 95% confidence interval, 1.95-12.50; P < 0.001). Within this subset, IPF-LTRs who had short telomeres had the highest risk of CMV complications (P < 0.01) including relapsing-viremia episodes, end-organ disease, and CMV resistance to therapy, as well as shorter time to viremia versus age-matched non-IPF control subjects (P < 0.001). The short telomere defect in IPF-LTRs was associated with significantly impaired CMV-specific proliferative responses, T-cell effector functions, and induction of the major type-1 transcription factor T-bet (T-box 21;TBX21). CONCLUSIONS: Because the short telomere defect has been linked to the pathogenesis of IPF in some cases, our data indicate that impaired CMV immunity may be a systemic manifestation of telomere-mediated disease in these patients. Identifying this high-risk subset of LTRs has implications for risk assessment, management, and potential strategies for averting post-transplant CMV morbidities.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Popescu I, Mannem H, Winters SA, et al. Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres. Am J Respir Crit Care Med. 2019. PMID: 30088779. doi:10.1164/rccm.201805-0825OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。